ZA200801169B - Stable solid formulation of sertindole - Google Patents

Stable solid formulation of sertindole

Info

Publication number
ZA200801169B
ZA200801169B ZA200801169A ZA200801169A ZA200801169B ZA 200801169 B ZA200801169 B ZA 200801169B ZA 200801169 A ZA200801169 A ZA 200801169A ZA 200801169 A ZA200801169 A ZA 200801169A ZA 200801169 B ZA200801169 B ZA 200801169B
Authority
ZA
South Africa
Prior art keywords
sertindole
solid formulation
stable solid
stable
formulation
Prior art date
Application number
ZA200801169A
Other languages
English (en)
Inventor
Flemming Enok Olsen
Anne Ravnholdt Christensen
Ken Liljegren
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of ZA200801169B publication Critical patent/ZA200801169B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200801169A 2005-09-08 2006-09-06 Stable solid formulation of sertindole ZA200801169B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200501255 2005-09-08

Publications (1)

Publication Number Publication Date
ZA200801169B true ZA200801169B (en) 2010-07-28

Family

ID=37697999

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200801169A ZA200801169B (en) 2005-09-08 2006-09-06 Stable solid formulation of sertindole

Country Status (17)

Country Link
EP (1) EP1924261A1 (uk)
JP (1) JP2009507051A (uk)
KR (1) KR20080042102A (uk)
CN (1) CN101257906A (uk)
AR (1) AR056475A1 (uk)
AU (1) AU2006322460A1 (uk)
BR (1) BRPI0615630A2 (uk)
CA (1) CA2621866A1 (uk)
EA (1) EA013167B1 (uk)
IL (1) IL189541A0 (uk)
MX (1) MX2008002290A (uk)
NO (1) NO20081721L (uk)
NZ (1) NZ565330A (uk)
TW (1) TW200738239A (uk)
UA (1) UA97349C2 (uk)
WO (1) WO2007065448A1 (uk)
ZA (1) ZA200801169B (uk)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
JP5591128B2 (ja) * 2009-01-29 2014-09-17 大日本住友製薬株式会社 内核を有する口腔内崩壊錠
FR2943061B1 (fr) * 2009-03-13 2011-02-25 Rhodia Operations Composes organophosphores, systemes catalytiques comprenant ces composes et procede d'hydrocyanation ou d'hydroformylation utilisant ces systemes catalytiques
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
SI3470397T1 (sl) 2012-07-16 2022-07-29 Fibrogen, Inc. Kristalinične oblike zaviralca prolil hidroksilaze
DK3003284T3 (da) * 2013-06-06 2020-03-30 Fibrogen Inc Farmaceutiske formuleringer af en hif-hydroxylase-inhibitor
EP3043793B1 (en) * 2013-11-19 2021-01-06 Siga Technologies Inc. Rehydration of micronized tecovirimat monohydrate
JP2018172361A (ja) * 2016-10-14 2018-11-08 大原薬品工業株式会社 光安定性を改善した、デュロキセチンを含有する固形製剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04346929A (ja) * 1991-05-22 1992-12-02 Takada Seiyaku Kk 光に安定なメシル酸ブロモクリプチン製剤
EP0906104A4 (en) * 1996-03-25 2003-12-10 Lilly Co Eli PAIN TREATMENT PROCESS
ZA973433B (en) * 1996-04-24 1997-12-10 Shionogi & Co A sertindole-containing preparation and a method for producing the same.
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses

Also Published As

Publication number Publication date
JP2009507051A (ja) 2009-02-19
UA97349C2 (uk) 2012-02-10
WO2007065448A1 (en) 2007-06-14
EA013167B1 (ru) 2010-02-26
BRPI0615630A2 (pt) 2016-11-16
AU2006322460A1 (en) 2007-06-14
EA200800774A1 (ru) 2008-06-30
TW200738239A (en) 2007-10-16
MX2008002290A (es) 2008-03-14
EP1924261A1 (en) 2008-05-28
CN101257906A (zh) 2008-09-03
AR056475A1 (es) 2007-10-10
NZ565330A (en) 2011-06-30
KR20080042102A (ko) 2008-05-14
CA2621866A1 (en) 2007-06-14
IL189541A0 (en) 2008-08-07
NO20081721L (no) 2008-04-08

Similar Documents

Publication Publication Date Title
GB2424581B (en) Formulations
PL2335782T3 (pl) Zastosowanie kompozycji zawierającej HFCO-1233zd
ZA200808773B (en) Stable emulsion formulations
IL188915A0 (en) Liquid formulations
ZA200801773B (en) New formulation
EP1909584A4 (en) PRENYLFLAVONOID FORMULATIONS
HK1198914A1 (en) Novel dosage formulation
TWI370115B (en) New formulation
GB0507208D0 (en) Anti-inflammatory formulation
IL189935A0 (en) Solid formulation of fungicidal mixtures
GB0526419D0 (en) Formulation
GB0505569D0 (en) Formulations
EP1951693A4 (en) SOLID FORMULATIONS
GB0517673D0 (en) Formulation
IL189541A0 (en) Stable solid formulation of sertindole
EP1894565A4 (en) STABILIZED MILNACIPRANE FORMULATION
ZA200802953B (en) Solid vaccine formulation
GB0501030D0 (en) Formulation
HK1120414A1 (en) Pharmaceutical formulation of nitrooxyderivatives of nsaids
PL1928232T3 (pl) Stała formulacja
EP1951258A4 (en) LIQUID FORMULATIONS
GB0507811D0 (en) Formulation
GB0500807D0 (en) Formulation
GB0510788D0 (en) Formulation
GB0518878D0 (en) Formulations